Out-of-hospital market breaks out, prescription circulation rules are released, injections are excluded

It is understood that the first batch of pilot hospitals include the Third Xiangya Hospital of Central South University, Hunan Cancer Hospital, Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha Central Hospital, Changsha First Hospital, Changsha Third Hospital and Shimen County People's Hospital .
After the pilot, it will be gradually promoted to the second and third-level medical institutions across the province.

Hunan requires that the drugs that can be extended should be mainly oral or topical preparations for chronic diseases and common diseases, injections (except for self-use insulin needles), psychotropic drugs, anesthetics, medical toxic drugs, radiopharmaceuticals and other medications with high risk or need Specially managed drugs are not included in the scope of prescription circulation.

Clarify pharmacy access conditions and exit mechanism

Violation of the rules is strictly prohibited

In order to further deepen the reform of public hospitals, improve the residents' experience in purchasing medicines, and improve the service level of medical and health convenience, Hunan Province formulated the "Trial Plan" in accordance with the spirit of the "Opinions on Promoting the Development of "Internet + Medical Health"" issued by the State Council.
.

The "Trial Plan" proposes to establish a unified prescription circulation and supervision platform across the province, realize the circulation of prescription data in various medical institutions, and carry out hospital prescription extension (including hospital HIS system, Internet medical service system, etc.
), intelligent online review, and chronic disease continued.
Prescriptions, rational drug use monitoring and other tasks, to achieve online supervision of prescription circulation by the provincial, municipal, and county health administrative departments.

  Meanwhile, the body to carry out the prescription service system construction.
Based on the prescription circulation and supervision platform of Hunan Province, we will innovate the traditional medicine dispensing service model, establish a prescription service system, connect the patient, doctor, pharmacy and management side, and provide the majority of patients with prescription extension, appointment purchase, medication consultation, etc.
" Internet + medical and health" services.
Patients can choose to buy medicines at medical institutions or retail pharmacies by relying on electronic prescriptions for common diseases and chronic diseases issued by the hospital, and after being reviewed by a pharmacist.

  From the perspective of specific implementation, pilot hospitals must combine actual conditions to clarify the physicians, pharmacists and drug catalogs that can be extended by the institution that can carry out prescription circulation.
Retail pharmacies can voluntarily participate in the circulation and supervision platform according to the pharmacy access conditions, and connect to the retail pharmacy management information system.

  Regarding the access conditions and exit mechanism of retail pharmacies, Hunan requires that retail pharmacies voluntarily apply for access, adopt a commitment system, and should meet the following conditions: they have not been subject to administrative penalties by regulatory authorities due to major violations of laws and regulations within the past year, and they have The prescription sharing platform instantly uploads the basic conditions for storing drug codes, prices and other information in each store; during business hours, a retail pharmacy licensed pharmacist is on duty or a retail chain pharmacy meets the remote review conditions determined by the "Hunan Province Licensed Pharmacist Remote Review Setting Specification", It can also conduct real-time prescription review and guide rational drug use; retail pharmacies that have not conducted remote review should be equipped with a licensed pharmacist, and those who operate Chinese medicine decoctions should also be equipped with a licensed Chinese pharmacist (a licensed pharmacist and a licensed Chinese pharmacist should be equipped with a double certificate).
Yes), real-time guidance of medication; all clearly marked pharmacy service areas in the business premises; provision of medicines consistent with the circulation prescriptions of the hospital, etc.

  Hunan also puts forward strict requirements on pharmacies connected to the prescription circulation platform.
If there is: refuse to open the information and data involved in the circulation of prescriptions; change the drugs listed in the circulation prescriptions of the hospital without authorization; insufficient drug reserves prevent patients from being able to pick up the drugs in the store.
The investigation and verification has accumulatively reached 10 times or more each year; violations of regulations; failure to conduct prescription drug review as required; serious violations of the "Pharmaceutical Business Quality Management Standards" and other violations of laws and regulations will bear corresponding legal liabilities and cancel participation Qualifications, and no application is allowed within two years.

  Speed ​​up prescription outflow

  The out-of-hospital market welcomes good

  In recent years, a prescription transfer platform model similar to Hunan has been launched in some regions.
Shandong, Jiangxi, Gansu, Guangdong and other provinces and cities are actively exploring prescription transfer models established under government supervision.

  On March 25, 28 departments including the National Development and Reform Commission, the Central Cyberspace Administration of China, the Ministry of Education, the Ministry of Industry and Information Technology, the National Health Commission, the National Food and Drug Administration, and the National Medical Insurance Bureau formulated the "Accelerating the Cultivation of New Consumption The "Implementation Plan" proposes to issue guidance documents for the circulation of electronic prescriptions, improve the design of technical routes, and strengthen integrated online and offline supervision.
With the introduction of the guidance document policy in the future, the implementation of the electronic prescription circulation model may accelerate.

  In the view of the industry, the prescription circulation platform will also become the main carrier of prescription outflow.
With the launch of the provincial-level prescription circulation platform, it will have a huge impact on the flow of prescription drugs in the regional market, and will also bring more traffic opportunities to the retail pharmacies undertaking.

  The circulation of prescriptions is a specific measure to deepen the reform of the medical and health system and promote the development of "Internet + medical and health" services.

  With the implementation of a series of medical reform measures such as the proportion of medicines, zero mark-up rate, graded diagnosis and treatment, consistency evaluation, medical insurance control fees, and volume purchases, as well as the continuous innovation of the "Internet +" model, the Internet + "medical, pharmaceutical, medical insurance" three The medical linkage model has gradually formed.
Since 2020, the impact of the epidemic has been superimposed, the separation of medicines, the outflow of prescriptions from hospitals has significantly accelerated, and the out-of-hospital market continues to expand.

  A research organization reported that by 2028, the market size of prescription outflows will exceed 720 billion yuan, and chain pharmacies will undertake 500 billion yuan.
With the further implementation of the "medicine separation" policy, the outflow of prescriptions in the future will directly benefit medical insurance stores, hospital stores and DTP pharmacies.
There are also views that with the advancement of medical reform policies, outpatient pharmacies in hospitals may be cancelled in the future.

  It is worth noting that the outflow of prescriptions for innovative drugs has become a major trend when many medical insurance negotiated drugs cannot enter the hospital channels.
According to a data provided by Tongji Medical College of Huazhong University of Science and Technology, the sales channels of innovative drugs that have been on the market in the past two years are mainly in DTP pharmacies (up to 90% of sales) rather than hospitals.
According to data from Mi Nei.
com, in 2020, in urban physical pharmacies, anti-tumor drugs will show a high growth trend with high prices and the addition of a variety of new drugs, and will enter the first place in the drug sub-category with a compound growth rate of up to 60.
8%.

  Based on this, the National Medical Insurance Administration and the National Health Commission recently issued the "Guiding Opinions on Establishing and Improving the "Dual Channel" Management Mechanism for Drugs in National Medical Insurance Negotiations".
Channel" management.
This is also regarded by the industry as a new starting point for the out-of-hospital market.
The "dual channel" management mechanism also mentioned that it will rely on a unified national medical insurance information platform to deploy prescription circulation centers, connect medical insurance agencies, designated medical institutions, and designated retail pharmacies to ensure the smooth circulation of electronic prescriptions.

  For enterprises, the internal and external markets are also facing new layout strategies.
Industrial enterprises, represented by multinational pharmaceutical companies, have increased their investment in the out-of-hospital retail market, especially for products that have not won bids from the country.
More and more pharmaceutical industry companies and innovative pharmaceutical companies have also announced the launch of a new retail strategy for prescription drugs.
At the same time, pharmaceutical distribution giants such as National Control, Shanghai Pharmaceuticals, and China Resources, and large chain pharmacies, as an important force in undertaking prescription outflow, continue to actively deploy and make sufficient preparations to undertake prescription outflow.
(Pharmaceutical Economic News)